Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen GAAP Cost of Sales as % of Product Sales by Quarter
GAAP Cost of Sales as % of Product Sales (%) (%)
Amgen GAAP Cost of Sales as % of Product Sales: 29.5% in Q2 2026, down 4.8 pts from a year earlier.
Latest, Q2 2026
29.5%
Period ended Jun 30, 2026
Change on a year earlier
-4.8 pts
34.3% in Q2 2025
History
36 quarters
Since Q3 2017
Sources
32
Documents cited below
Where the Q2 2026 figure comes from
“|| GAAP cost of sales as a percentage of product sales | 29.5 | % | 34.3 | % | 31.3 | % | 35.9 | %”
Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen GAAP Cost of Sales as % of Product Sales (%), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-cogs-pct
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.